<DOC>
	<DOCNO>NCT00274937</DOCNO>
	<brief_summary>This phase III trial study well radiation therapy , amifostine , chemotherapy work treat young patient newly diagnose nasopharyngeal cancer . Radiation therapy use high-energy x-ray kill tumor cell . Drugs , amifostine , may protect normal cell side effect radiation therapy . Drugs use chemotherapy , cisplatin fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together amifostine chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Radiation Therapy , Amifostine , Chemotherapy Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate , overall survival , event-free survival child advance nasopharyngeal carcinoma treat induction chemotherapy follow concurrent chemoradiotherapy amifostine . SECONDARY OBJECTIVES : I . Characterize role Epstein-Barr virus ( EBV ) pathogenesis nasopharyngeal carcinoma child . II . Investigate predictive value detection EBV DNA peripheral blood child nasopharyngeal carcinoma . III . Determine incidence NUT rearrangement childhood nasopharyngeal carcinoma . IV . Determine radioprotective effect amifostine give daily prior radiation therapy . OUTLINE : This nonrandomized , multicenter study . Patients stratify accord stage disease ( I IIA [ stratum I ] vs IIB-IV [ stratum II ] ) . STRATUM I : Patients undergo radiotherapy 5 day week 8 week . Patients also receive amifostine subcutaneously day undergo radiotherapy . STRATUM II : INDUCTION THERAPY ( week 1-9 ) : Patients receive cisplatin IV 6 hour day 1 fluorouracil IV continuously day 1-4 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients respond stable disease proceed consolidation therapy . CONSOLIDATION THERAPY ( week 10-18 ) : Patients undergo radiotherapy receive amifostine stratum I . Patients also receive cisplatin IV 6 hour day 1 22 ( 2 course ) . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>Histological diagnosis nasopharyngeal carcinoma WHO type II III Stage IIV disease Newly diagnose disease Performance status Patients ≤ 16 year age : Lansky 60100 % Patients &gt; 16 year age : Karnofsky 60100 % Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min Creatinine base age/gender follow : No great 0.4 mg/dL ( patient 1 month &lt; 6 month age ) No great 0.5 mg/dL ( patient 6 month &lt; 1 year age ) No great 0.6 mg/dL ( patient 12 year age ) No great 0.8 mg/dL ( patient &lt; 6 year age ) No great 1.0mg/dL ( patient 6 &lt; 10 year age ) No great 1.2 mg/dL ( patient 10 &lt; 13 year age ) No great 1.4 mg/dL ( female patient 13 ≥ 16 year age ) No great 1.5 mg/dL ( male patient 13 &lt; 16 year age ) No great 1.7 mg/dL ( male patient ≥ 16 year age ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 2.5 time ULN age Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior chemotherapy radiotherapy nasopharynx neck treatment nasopharyngeal carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>